Hashimotos Chronic Thyroiditis treated with Systemic Ozone

Background

Hashimoto's thyroiditis (HT) is a chronic autoimmune condition in which the immune system gradually damages the thyroid gland, often leading to reduced thyroid hormone production over time. Researchers have increasingly linked HT to raised levels of oxidative stress (OS) - an imbalance between damaging free radicals and the body's antioxidant defences - which is thought to contribute to the ongoing immune dysfunction seen in the disease. This has led some clinicians to investigate whether systemic ozone therapy, which has been studied for its potential to modulate oxidative stress and immune activity, could offer supportive benefit for people living with HT.

Study design

This work was published as a preliminary abstract by Hernandez-Rosales and Picrin-Duany in the Journal of Ozone Therapy (Universitat de Valencia) in 2019. As only the abstract of this work has been made publicly available, the full methodology - including the exact number of patients treated, the specific ozone application method (such as major autohaemotherapy or rectal insufflation), dosing schedule, and any comparison or control group - is not detailed in the accessible text. The authors describe their findings as preliminary results relating to patients with HT.

Findings

The authors report that their preliminary results suggest systemic ozone therapy may help provide protection against the oxidative stress associated with Hashimoto's thyroiditis. No specific numerical outcome data (such as changes in antioxidant markers or thyroid antibody levels) are given in the published abstract text.

What the authors concluded

The authors conclude that systemic ozone therapy may be helpful in providing protection against oxidative stress in this disease, but they are explicit that further long-term treatment studies are needed to properly establish the effectiveness of this therapy on the immune system disorders seen in patients with Hashimoto's thyroiditis.

Limitations of this study

This work has only been published as a short congress/journal abstract, not as a full peer-reviewed paper, so key details such as sample size, study design (case report versus case series), blinding, and statistical analysis cannot be independently verified from the publicly available text. The authors themselves describe the results as preliminary. No long-term follow-up data are reported. As with all early-stage or abstract-only findings, these results should be treated as hypothesis-generating rather than conclusive evidence of clinical benefit, and should not be used as a basis for changing thyroid treatment without discussing this with a qualified healthcare practitioner.